{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:54:01Z","timestamp":1781639641586,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hyperemesis gravidarum (HG) is characterized by severe nausea and vomiting during pregnancy, and can markedly impair quality of life as well as cause maternal and fetal complications. Although a stepwise treatment strategy with antiemetics and nutritional support is commonly used, some cases remain refractory. Olanzapine, an atypical antipsychotic, has shown potential benefit in HG, although most reports involve patients with psychiatric comorbidities. We describe a patient with persistent HG in late gestation without psychiatric history, in whom adjunctive olanzapine was temporally associated with improvement in nausea and vomiting symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 42-year-old woman (Gravida 2, Para 0) conceived through frozen-thawed embryo transfer and was diagnosed with HG at gestational week 8. Despite intravenous fluids and metoclopramide, symptoms persisted, and she was hospitalized at 32 weeks due to poor maternal weight gain and fetal growth restriction. On admission, her nausea was severe (Numerical Rating Scale [NRS]: 10), with a Pregnancy-Unique Quantification of Emesis and Nausea (PUQE-24) score of 15 and persistent vomiting up to 18 episodes\/day. Despite no prior psychiatric history, she developed depressive symptoms during pregnancy. Olanzapine was started at 2.5 mg\/day and titrated to 10 mg\/day by 35 weeks; total parenteral nutrition was initiated concurrently. By 35 weeks, her nausea improved (NRS: 10\/10 to 3.5\/10; PUQE-24: 15 to 9) and vomiting decreased to 9 episodes\/day. A cesarean section was performed at 35 weeks and 2 days owing to acute pulmonary edema. A 2,160-g female infant was delivered with Apgar scores of 2, 4, and 5. The neonate was admitted to the neonatal intensive care unit due to transient respiratory distress (ventilation: 2 days; oxygen: 10 days), with a normal brain MRI prior to discharge and no evidence of hypoxic\u2013ischemic encephalopathy. Maternal gastrointestinal symptoms resolved immediately after delivery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case highlights the potential role of olanzapine in refractory HG management, even in the absence of pre-existing psychiatric comorbidities. It also underscores the importance of early nutritional intervention and multidisciplinary management, particularly when prolonged symptoms contribute to declining quality of life and depressive affect. Further case reports are required to confirm this therapeutic effect of olanzapine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12884-026-08893-w","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T05:55:38Z","timestamp":1772517338000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of olanzapine for hyperemesis gravidarum in individuals without a psychiatric history: a case report"],"prefix":"10.1186","volume":"26","author":[{"given":"Hiromitsu","family":"Kaneko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Tanimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuneaki","family":"Kenzaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"8893_CR1","doi-asserted-by":"publisher","unstructured":"ACOG Practice Bulletin No. 189: Nausea and vomiting of pregnancy. Obstet Gynecol. 2018;131:e15\u2013e30. https:\/\/doi.org\/10.1097\/AOG.0000000000002456","DOI":"10.1097\/AOG.0000000000002456"},{"key":"8893_CR2","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.jogc.2016.08.009","volume":"38","author":"K Campbell","year":"2016","unstructured":"Campbell K, Rowe H, Afi J, Lackey C, Kriebs J, Abell D, et al. The management of nausea and vomiting of pregnancy. J Obstet Gynaecol Can. 2016;38:1127\u201337. https:\/\/doi.org\/10.1016\/j.jogc.2016.08.009.","journal-title":"J Obstet Gynaecol Can"},{"key":"8893_CR3","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1001\/jama.2016.14337","volume":"316","author":"C McParlin","year":"2016","unstructured":"McParlin C, O\u2019Donnell A, Robson SC, Beyer F, Moloney E, Bryant A, et al. Treatments for hyperemesis gravidarum and nausea and vomiting in pregnancy: a systematic review. JAMA. 2016;316:1392\u2013401. https:\/\/doi.org\/10.1001\/jama.2016.14337.","journal-title":"JAMA"},{"key":"8893_CR4","doi-asserted-by":"publisher","unstructured":"Lee NM, Saha S. Nausea and vomiting of pregnancy. Gastroenterol Clin North Am. 2011;40:309\u201334, vii. https:\/\/doi.org\/10.1016\/j.gtc.2011.03.009","DOI":"10.1016\/j.gtc.2011.03.009"},{"key":"8893_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/1471-0528.14180","volume":"124","author":"N Mitchell-Jones","year":"2017","unstructured":"Mitchell-Jones N, Gallos I, Farren J, Tobias A, Bottomley C, Bourne T. Psychological morbidity associated with hyperemesis gravidarum: a systematic review and meta-analysis. BJOG. 2017;124:20\u201330. https:\/\/doi.org\/10.1111\/1471-0528.14180.","journal-title":"BJOG"},{"key":"8893_CR6","doi-asserted-by":"publisher","first-page":"S232","DOI":"10.1067\/mob.2002.122604","volume":"186","author":"LA Magee","year":"2002","unstructured":"Magee LA, Chandra K, Mazzotta P, Stewart D, Koren G, Guyatt GH. Development of a health-related quality of life instrument for nausea and vomiting of pregnancy. Am J Obstet Gynecol. 2002;186:S232\u20138. https:\/\/doi.org\/10.1067\/mob.2002.122604.","journal-title":"Am J Obstet Gynecol"},{"key":"8893_CR7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1477-7525-6-32","volume":"6","author":"A Lacasse","year":"2008","unstructured":"Lacasse A, B\u00e9rard A. Validation of the nausea and vomiting of pregnancy specific health related quality of life questionnaire. Health Qual Life Outcomes. 2008;6:32. https:\/\/doi.org\/10.1186\/1477-7525-6-32.","journal-title":"Health Qual Life Outcomes"},{"key":"8893_CR8","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.ijgo.2016.01.023","volume":"134","author":"V Dochez","year":"2016","unstructured":"Dochez V, Dimet J, David-Gruselle A, Le Thuaut A, Ducarme G. Validation of specific questionnaires to assess nausea and vomiting of pregnancy in a French population. Int J Gynaecol Obstet. 2016;134:294\u20138. https:\/\/doi.org\/10.1016\/j.ijgo.2016.01.023.","journal-title":"Int J Gynaecol Obstet"},{"key":"8893_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ejogrb.2019.03.006","volume":"236","author":"E Oudman","year":"2019","unstructured":"Oudman E, Wijnia JW, Oey MJ, van Dam M, Painter RC, Postma A. Wernicke\u2019s encephalopathy in hyperemesis gravidarum: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2019;236:84\u201393. https:\/\/doi.org\/10.1016\/j.ejogrb.2019.03.006.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"8893_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.autneu.2016.05.002","volume":"202","author":"M Bustos","year":"2017","unstructured":"Bustos M, Venkataramanan R, Caritis S. Nausea and vomiting of pregnancy \u2013 what\u2019s new? Auton Neurosci. 2017;202:62\u201372. https:\/\/doi.org\/10.1016\/j.autneu.2016.05.002.","journal-title":"Auton Neurosci"},{"key":"8893_CR11","doi-asserted-by":"publisher","first-page":"809270","DOI":"10.3389\/fmed.2021.809270","volume":"8","author":"J Liu","year":"2022","unstructured":"Liu J, Farhat YA, Al-Saffar A, MacGibbon KW, Fejzo MS, Goodwin TM, et al. Emerging progress in nausea and vomiting of pregnancy and hyperemesis gravidarum: challenges and opportunities. Front Med (Lausanne). 2022;8:809270. https:\/\/doi.org\/10.3389\/fmed.2021.809270.","journal-title":"Front Med (Lausanne)"},{"key":"8893_CR12","unstructured":"Royal College of Obstetricians & Gynaecologists. The Management of Nausea and Vomiting of Pregnancy and Hyperemesis Gravidarum (Green-top Guideline No.69). https:\/\/www.rcog.org.uk\/guidance\/browse-all-guidance\/green-top-guidelines\/the-management-of-nausea-and-vomiting-of-pregnancy-and-hyperemesis-gravidarum-green-top-guideline-no-69\/#:~:text=This%20guideline%20gives%20clinical%20advice,for%20women%20and%20their%20families. Accessed 4 Feb 2026."},{"key":"8893_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/OGX.0000000000000746","volume":"75","author":"D Spinosa","year":"2020","unstructured":"Spinosa D, Post A, Kuller JA, Dotters-Katz S. Management Considerations for Recalcitrant Hyperemesis. Obstet Gynecol Surv. 2020;75:50\u201360. https:\/\/doi.org\/10.1097\/OGX.0000000000000746.","journal-title":"Obstet Gynecol Surv"},{"key":"8893_CR14","doi-asserted-by":"publisher","first-page":"214","DOI":"10.4274\/tjod.78477","volume":"14","author":"Y Topalahmeto\u011flu","year":"2017","unstructured":"Topalahmeto\u011flu Y, Altay MM, C\u0131r\u0131k DA, Tohma YA, \u00c7olak E, \u00c7o\u015fkun B, et al. Depression and anxiety disorder in hyperemesis gravidarum: A prospective case-control study. Turk J Obstet Gynecol. 2017;14:214. https:\/\/doi.org\/10.4274\/tjod.78477.","journal-title":"Turk J Obstet Gynecol"},{"key":"8893_CR15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/2050-6511-14-38","volume":"14","author":"E Brunner","year":"2013","unstructured":"Brunner E, Falk DM, Jones M, Dey DK, Shatapathy CC. Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. BMC Pharmacol Toxicol. 2013;14:38. https:\/\/doi.org\/10.1186\/2050-6511-14-38.","journal-title":"BMC Pharmacol Toxicol"},{"key":"8893_CR16","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1111\/jocn.14705","volume":"28","author":"L Wikstr\u00f6m","year":"2019","unstructured":"Wikstr\u00f6m L, Nilsson M, Brostr\u00f6m A, Eriksson K. Patients\u2019 self-reported nausea: Validation of the Numerical Rating Scale and of a daily summary of repeated Numerical Rating Scale scores. J Clin Nurs. 2019;28:959\u201368. https:\/\/doi.org\/10.1111\/jocn.14705.","journal-title":"J Clin Nurs"},{"key":"8893_CR17","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S1701-2163(16)34298-0","volume":"31","author":"N Ebrahimi","year":"2009","unstructured":"Ebrahimi N, Maltepe C, Bournissen FG, Koren G. Nausea and vomiting of pregnancy: using the 24-hour Pregnancy-Unique Quantification of Emesis (PUQE-24) scale. J Obstet Gynaecol Can. 2009;31:803\u20137. https:\/\/doi.org\/10.1016\/S1701-2163(16)34298-0.","journal-title":"J Obstet Gynaecol Can"},{"key":"8893_CR18","doi-asserted-by":"publisher","first-page":"7324627","DOI":"10.1155\/2022\/7324627","volume":"2022","author":"MAK Galletta","year":"2022","unstructured":"Galletta MAK, Tess VLC, Pasotti IM, Pelegrini LF, Rocha NKR, Testa CB, et al. Use of mirtazapine and olanzapine in the treatment of refractory hyperemesis gravidarum: a case report and systematic review. Case Rep Obstet Gynecol. 2022;2022:7324627. https:\/\/doi.org\/10.1155\/2022\/7324627.","journal-title":"Case Rep Obstet Gynecol"},{"key":"8893_CR19","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ejphar.2013.08.048","volume":"722","author":"RM Navari","year":"2014","unstructured":"Navari RM. Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2014;722:180\u20136. https:\/\/doi.org\/10.1016\/j.ejphar.2013.08.048.","journal-title":"Eur J Pharmacol"},{"key":"8893_CR20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40263-018-0525-x","volume":"32","author":"P Damkier","year":"2018","unstructured":"Damkier P, Videbech P. The safety of second-generation antipsychotics during pregnancy: a clinically focused review. CNS Drugs. 2018;32:351\u201366. https:\/\/doi.org\/10.1007\/s40263-018-0525-x.","journal-title":"CNS Drugs"},{"key":"8893_CR21","unstructured":"European Medicines Agency. Olanzapine Teva: EPAR - Product Information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/olanzapine-teva-epar-product-information_en.pdf. Accessed 4 Feb 2026."},{"key":"8893_CR22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/sj.npp.1300027","volume":"28","author":"WK Kroeze","year":"2003","unstructured":"Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28:519\u201326. https:\/\/doi.org\/10.1038\/sj.npp.1300027.","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"8893_CR23","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40263-022-00908-2","volume":"36","author":"E Heinonen","year":"2022","unstructured":"Heinonen E, Forsberg L, N\u00f6rby U, Wide K, K\u00e4ll\u00e9n K. Antipsychotic Use During Pregnancy and Risk for Gestational Diabetes: A National Register-Based Cohort Study in Sweden. CNS Drugs. 2022;36(5):529\u201339. https:\/\/doi.org\/10.1007\/s40263-022-00908-2.","journal-title":"CNS Drugs"},{"key":"8893_CR24","first-page":"1042","volume":"55","author":"M Kanemori","year":"2019","unstructured":"Kanemori M, Seki N, Etou E, Hirano Y, Masuyama H. A case report on the usefulness of olanzapine for hyperemesis gravidarum. J Jpn Soc Perin Neon Med. 2019;55:1042\u20136.","journal-title":"J Jpn Soc Perin Neon Med"},{"key":"8893_CR25","doi-asserted-by":"publisher","first-page":"9532","DOI":"10.1080\/14767058.2022.2046730","volume":"35","author":"V Sharma","year":"2022","unstructured":"Sharma V, Sharma S, Hutson J, Martin A. A potential role for olanzapine in the treatment of hyperemesis gravidarum. J Matern Fetal Neonatal Med. 2022;35:9532\u20135. https:\/\/doi.org\/10.1080\/14767058.2022.2046730.","journal-title":"J Matern Fetal Neonatal Med"},{"key":"8893_CR26","doi-asserted-by":"publisher","first-page":"102751","DOI":"10.1016\/j.jogc.2024.102751","volume":"47","author":"V Sharma","year":"2025","unstructured":"Sharma V, Wood KN. Effect of olanzapine on hyperemesis gravidarum in individuals with mood disorders: a case series. J Obstet Gynaecol Can. 2025;47:102751. https:\/\/doi.org\/10.1016\/j.jogc.2024.102751.","journal-title":"J Obstet Gynaecol Can"},{"key":"8893_CR27","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1097\/AOG.0000000000005518","volume":"143","author":"SM Clark","year":"2024","unstructured":"Clark SM, Zhang X, Goncharov DA. Inpatient management of hyperemesis gravidarum. Obstet Gynecol. 2024;143:745\u201358. https:\/\/doi.org\/10.1097\/AOG.0000000000005518.","journal-title":"Obstet Gynecol"},{"key":"8893_CR28","doi-asserted-by":"publisher","first-page":"20cr02905","DOI":"10.4088\/PCC.20cr02905","volume":"23","author":"V Sharma","year":"2021","unstructured":"Sharma V. Treatment of depression in a patient with intractable hyperemesis gravidarum. Prim Care Companion CNS Disord. 2021;23:20cr02905. https:\/\/doi.org\/10.4088\/PCC.20cr02905.","journal-title":"Prim Care Companion CNS Disord"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12884-026-08893-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-026-08893-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-026-08893-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:12:28Z","timestamp":1781637148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12884-026-08893-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8893"],"URL":"https:\/\/doi.org\/10.1186\/s12884-026-08893-w","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this report complies with those guidelines. Approval for this study was obtained from the Institutional Review Board of the Japanese Red Cross Society Himeji Hospital (approval number: 2025-57).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"380"}}